Advertisement

ADVERTISEMENT

Jordan Kadish

News
Blinatumomab During Consolidation May Benefit Patients With High-Risk Ph-Negative BCP Acute Lymphoblastic Leukemia
02/08/2023
Results from the GRAALL-2014/B 2-cohort comparison study presented at the 2022 ASH Annual Meeting & Exposition found blinatumomab during consolidation demonstrated a significant reduction of the risk of relapse among patients with high-risk...
Results from the GRAALL-2014/B 2-cohort comparison study presented at the 2022 ASH Annual Meeting & Exposition found blinatumomab during consolidation demonstrated a significant reduction of the risk of relapse among patients with high-risk...
Results from the GRAALL-2014/B...
02/08/2023
Oncology
News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Predictive Value of CIRS-Derived Comorbidity Index for Patients With R/R DLBCL Indicated for CAR T-Cell Therapy
08/30/2023
A simplified CIRS-derived comorbidity index predicted outcomes among patients with R/R diffuse large B-cell lymphoma indicated for CAR T-cell therapy, according to a retrospective analysis.
A simplified CIRS-derived comorbidity index predicted outcomes among patients with R/R diffuse large B-cell lymphoma indicated for CAR T-cell therapy, according to a retrospective analysis.
A simplified CIRS-derived...
08/30/2023
Oncology
News
Pharmacology Model Predicts Treatment Benefits of Mosunetuzumab Among Patients With Non-Hodgkin Lymphoma
03/23/2023
According to the phase 1/2 GO29781 trial, a quantitative systems pharmacology model predicted increased exposure to mosunetuzumab led to tumor size reduction among patients with non-Hodgkin lymphoma.
According to the phase 1/2 GO29781 trial, a quantitative systems pharmacology model predicted increased exposure to mosunetuzumab led to tumor size reduction among patients with non-Hodgkin lymphoma.
According to the phase 1/2...
03/23/2023
Oncology
News
Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma
02/01/2024
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status...
02/01/2024
Oncology
News
Zanubrutinib Yields Superior PFS and ORR Compared to Ibrutinib for Patients With R/R CLL/SLL
02/09/2023
A final analysis of the ALPINE randomized phase 3 study found that zanubritinib for patients with R/R CLL/SLL resulted in superior progression-free survival and overall remission rate compared with ibrutinib.
A final analysis of the ALPINE randomized phase 3 study found that zanubritinib for patients with R/R CLL/SLL resulted in superior progression-free survival and overall remission rate compared with ibrutinib.
A final analysis of the ALPINE...
02/09/2023
Oncology
News
Anti-GPRC5D CAR T-Cell Therapy for Patients With R/R MM
05/15/2023
According to a phase 2 trial, anti-GPRC5D CAR T-cell therapy yielded effective and safe outcomes among patients with R/R multiple myeloma, including those who had previously undergone anti-BCMA CAR T-cell therapy.
According to a phase 2 trial, anti-GPRC5D CAR T-cell therapy yielded effective and safe outcomes among patients with R/R multiple myeloma, including those who had previously undergone anti-BCMA CAR T-cell therapy.
According to a phase 2 trial,...
05/15/2023
Oncology
News
Non-High-Dose Cytarabine Chemotherapy Plus BTK Inhibitor Treatment Shows Promise Among Patients With Newly Diagnosed Mantle Cell Lymphoma
07/06/2023
According to a real-world multicenter study, non-high-dose cytarabine chemotherapy plus BTK inhibitor treatment may be a valuable first-line therapeutic option for younger patients with mantle cell lymphoma.
According to a real-world multicenter study, non-high-dose cytarabine chemotherapy plus BTK inhibitor treatment may be a valuable first-line therapeutic option for younger patients with mantle cell lymphoma.
According to a real-world...
07/06/2023
Oncology
News
FDA Grants Approval to Ivosidenib for Patients With R/R Myelodysplastic Syndromes With IDH1 Mutation
10/26/2023
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA granted approval for ivosidenib, a small molecule inhibitor of IDH1, in the treatment of patients with R/R myelodysplastic syndromes with IDH1 mutation.
On October 24, 2023, the FDA...
10/26/2023
Oncology
News
Pacritinib Exhibits Consistent Efficacy for Spleen and Symptom Response Among Patients With Myelofibrosis, Regardless of Cytopenias
12/05/2023
Pacritinib, a novel JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1, demonstrated consistent efficacy for spleen and symptom response among patients with myelofibrosis, regardless of cytopenias.
Pacritinib, a novel JAK1-sparing inhibitor of JAK2/IRAK1/ACVR1, demonstrated consistent efficacy for spleen and symptom response among patients with myelofibrosis, regardless of cytopenias.
Pacritinib, a novel JAK1-sparing...
12/05/2023
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use